{"id":"ceftriaxone-and-azithromycin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Abdominal pain"},{"rate":"1-5","effect":"Rash"},{"rate":"1-3","effect":"Headache"},{"rate":"1-3","effect":"Vomiting"},{"rate":"0.1-1","effect":"QT prolongation (azithromycin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone is a beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Azithromycin is a macrolide that binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis. Together, they provide synergistic activity against common respiratory bacteria including Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms like Mycoplasma and Chlamydia.","oneSentence":"This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a macrolide antibiotic to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:17.723Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Respiratory tract infections"},{"name":"Atypical pneumonia"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":"Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth","enrollment":56},{"nctId":"NCT03959527","phase":"PHASE3","title":"Zoliflodacin in Uncomplicated Gonorrhoea","status":"COMPLETED","sponsor":"Global Antibiotics Research and Development Partnership","startDate":"2019-11-06","conditions":"Gonorrhea","enrollment":1011},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":"Preterm Premature Rupture of Membranes (PPROM), Prophylaxis, Perinatal Outcomes","enrollment":40},{"nctId":"NCT05812820","phase":"NA","title":"Effects of Probiotic in Treatment of Persistent Diarrhea in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2022-07-01","conditions":"Diarrhea","enrollment":165},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04010539","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-21","conditions":"Gonorrhea","enrollment":628},{"nctId":"NCT06349122","phase":"PHASE4","title":"Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-08","conditions":"Bacterial Vaginosis, Vaginal Dysbiosis, Premature Delivery","enrollment":1292},{"nctId":"NCT06090565","phase":"PHASE4","title":"Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea","status":"COMPLETED","sponsor":"Bulovka Hospital","startDate":"2021-04-01","conditions":"Gonorrhea","enrollment":161},{"nctId":"NCT04870138","phase":"PHASE1","title":"Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-10","conditions":"Gonococcal Infection","enrollment":16},{"nctId":"NCT04869579","phase":"PHASE2","title":"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.","status":"UNKNOWN","sponsor":"CHRISTUS Health","startDate":"2021-08-15","conditions":"Covid19","enrollment":100},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","startDate":"2021-04-15","conditions":"COVID -19","enrollment":25},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04461925","phase":"PHASE1, PHASE2","title":"Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs","status":"UNKNOWN","sponsor":"Institute of Cell Therapy","startDate":"2020-05-02","conditions":"COVID-19 Pneumonia","enrollment":30},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT02605122","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia","status":"TERMINATED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2016-04","conditions":"Community-acquired Bacterial Pneumonia","enrollment":97},{"nctId":"NCT03113344","phase":"","title":"Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2017-06-21","conditions":"Children; Infection","enrollment":800},{"nctId":"NCT02210325","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-08","conditions":"Uncomplicated Urogenital Gonorrhea","enrollment":264},{"nctId":"NCT02775968","phase":"","title":"Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2017-06-21","conditions":"Community Acquired Pneumonia","enrollment":750},{"nctId":"NCT01150747","phase":"","title":"Chlamydia Trachomatis Immunology and Vaccinology Study","status":"COMPLETED","sponsor":"Harold Wiesenfeld","startDate":"2011-01","conditions":"Chlamydia","enrollment":347},{"nctId":"NCT00717561","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-02","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT02224040","phase":"PHASE4","title":"Typhoid Fever: Combined vs. Single Antibiotic Therapy","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2013-08","conditions":"Typhoid Fever","enrollment":120},{"nctId":"NCT00644150","phase":"NA","title":"Effectiveness of HIV/Sexually Transmitted Infection Training for Physicians in China","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-04","conditions":"HIV Infections, Gonorrhea, Chlamydia","enrollment":1373}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ceftriaxone and azithromycin","genericName":"ceftriaxone and azithromycin","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a macrolide antibiotic to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens. Used for Community-acquired pneumonia, Respiratory tract infections, Atypical pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}